MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ccd.30161

Медицинская библиотека · Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2022

Mitral valve-in-valve and valve-in-ring procedures: Midterm outcomes in a French nationwide registry.

Le Ruz Robin, Guérin Patrice, Leurent Guillaume, Leroux Lionel, Lefevre Thierry, Nejjari Mohammed, Champagnac Didier, Tchétché Didier, Lhermusier Thibault, Senage Thomas, Piriou Pierre-Guillaume, Caussin Christophe, Delomez Maxence, Bonnet Guillaume, Favereau Xavier, Karam Nicole, Gerbay Antoine, Juthier Francis, Gilard Martine, Obadia Jean-Francois, Iung Bernard, Manigold Thibaut

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

Report contemporary outcomes in patients included in the Mitragister registry and treated with transcatheter mitral valve implantation for failed surgical annuloplasty rings or deteriorated bioprosthesis.

BACKGROUND

Midterm survival rates have been reported, but little is known about contemporary morbimortality endpoints.

METHODS

The primary safety outcome was the technical success rate. The primary efficacy composite endpoint was a composite of cardiovascular mortality and heart failure hospitalizations.

RESULTS

From 2016 to 2021, 102 patients (median age: 81 [74;84] years, 61% female, Euroscore II 11.0% [7.8;16.0]) undergoing valve-in-valve (ViV; n = 89) or valve-in-ring (ViR; n = 13) procedures were consecutively included. At baseline, ViR group patients had worse left ventricular ejection fraction (50% vs. 60%; p = 0.004) and more frequently severe regurgitation (46% vs. 15%; p = 0.014). The primary safety outcome was 95%: 77% and 98% in the ViR and ViV populations, respectively, (p = 0.014). At intermediate follow-up (6-12 months) clinical improvement was notable, 88% of the patients were in NYHA class ≤ II (vs. 25% at baseline; p < 0.001). At a mean follow-up of 17.1 ± 11.0 months, the primary efficacy composite reached 27%. By multivariate analysis, paravalvular leak (PVL) was the only independent predictor (hazard ratio: 2.39, 95% confidence interval: 1.08-5.29; p = 0.031) while ViR was not found statistically associated (p = 0.456).

CONCLUSIONS

This study confirms the safety and efficacy of the mitral ViV procedure. ViR patients appear at higher risk of procedural complications. The presence of PVL could be associated with markedly worse midterm prognosis. Whatever the intervention, procedural strategies to reduce PVL incidence remain to be assessed to prevent latter adverse outcomes.

Для цитирования: Le Ruz Robin, Guérin Patrice, Leurent Guillaume, Leroux Lionel, Lefevre Thierry, Nejjari Mohammed, Champagnac Didier, Tchétché Didier, Lhermusier Thibault, Senage Thomas, Piriou Pierre-Guillaume, Caussin Christophe, Delomez Maxence, Bonnet Guillaume, Favereau Xavier, Karam Nicole, Gerbay Antoine, Juthier Francis, Gilard Martine, Obadia Jean-Francois, Iung Bernard, Manigold Thibaut. Mitral valve-in-valve and valve-in-ring procedures: Midterm outcomes in a French nationwide registry.. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2022. DOI: 10.1002/ccd.30161.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.